Results 71 to 80 of about 77,075 (344)

The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion. [PDF]

open access: yesPLoS ONE, 2016
The aim of our study was to evaluate the role of 18F-FDG PET/CT integrated imaging in differentiating malignant from benign pleural effusion.A total of 176 patients with pleural effusion who underwent 18F-FDG PET/CT examination to differentiate ...
Yajuan Sun   +3 more
doaj   +1 more source

Spectrum and outcome in patients with unilateral pleural effusion admitted in a tertiary care hospital

open access: yesJournal of Clinical and Scientific Research, 2022
Background: Unilateral pleural effusion is a challenge for a physician as the differential diagnosis is varied; sparse epidemiological data are available from India on this subject.
Neeraj Saini   +4 more
doaj   +1 more source

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK's Haematological Malignancy Research Network

open access: yesInternational Journal of Cancer, EarlyView.
Although tyrosine kinase inhibitors (TKIs) improve chronic myeloid leukemia (CML) outcome, long‐term effects remain unclear, particularly in real‐world settings. Here, the authors examined morbidity and mortality in CML patients treated with TKIs between 2009 and 2019 in the United Kingdom.
Eleanor Kane   +7 more
wiley   +1 more source

Repeat Thoracenteses Is Associated with an Increase in Cumulative Risk of Complications in Patients with a Malignant Pleural Effusion [PDF]

open access: gold, 2021
A. Meggyesy   +4 more
openalex   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori   +11 more
wiley   +1 more source

Diagnostic value of cyfra 21-1 and carcinoembryonic antigen in differentiation between benign and malignant pleural effusion

open access: yesEgyptian Journal of Chest Disease and Tuberculosis, 2015
Background: Tumor markers were used in malignant pleural effusion with negative cytology. Aim of the work: The aim was to assess the value of serum and pleural levels of cyfra 21-1 (fragment of cytokeratin 19) and carcinoembryonic antigen (CEA) in the ...
Waffa S. El-Shimy   +3 more
doaj   +1 more source

Ultrasound-Proven Efficacy of One Dose of Alteplase via Thoracentesis Catheter for a Loculated Malignant Pleural Effusion [PDF]

open access: gold, 2021
E. Mlodzinski   +3 more
openalex   +1 more source

Postoperative Weight Gain, Due to Fluid Retention After Ovarian Cancer Surgery—How Much Is too Much?

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives Postoperative complications after cytoreductive surgery in ovarian cancer patients are associated with impaired survival. Here, we investigated the association between postoperative weight gain due to fluid retention and the development of complications and anastomotic leakage (AL).
Eva K. Egger   +7 more
wiley   +1 more source

Diagnostic accuracy of tumor necrosis factor-alpha, interferon-gamma, interlukine-10 and adenosine deaminase 2 in differential diagnosis between tuberculous pleural effusion and malignant pleural effusion [PDF]

open access: yes, 2014
BACKGROUND: The current study was performed to investigate the potential biomarkers for the differential diagnosis of tuberculous pleural effusion (TPE) and malignant pleural effusions (MPE). METHODS: Among ninety patients (n = 90) involved in the study,
Helin Wang   +5 more
core   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

open access: yesMass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy